- Conditions
- Melanoma
- Interventions
- 6MHP, Pembrolizumab
- Biological · Drug
- Lead sponsor
- Craig L Slingluff, Jr
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 1
- States / cities
- Charlottesville, Virginia
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1513–1536
of 2,054
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Pancreatic Ductal Adenocarcinoma, Pancreatic Cyst, Chronic Pancreatitis, Fatty Pancreas, Genetic Pancreatic Cancer, Genetic Pancreatitis, BRCA Mutation, Lynch Syndrome, FAP, Familial Atypical Multiple Mole-Melanoma, PALB2 Gene Mutation, Peutz-Jeghers Syndrome, Ataxia Telangiectasia
- Interventions
- Data collection
- Other
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 317 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2027
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Metastatic Melanoma
- Interventions
- NEO-PV-01, Nivolumab, Adjuvant, APX005M, ipilimumab
- Biological · Other
- Lead sponsor
- BioNTech US Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 8
- States / cities
- Scottsdale, Arizona • Los Angeles, California • Denver, Colorado + 4 more
- Conditions
- Melanoma, Neoplasm Metastasis
- Interventions
- CC 5013
- Drug
- Lead sponsor
- Celgene Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 274 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2004
- U.S. locations
- 25
- States / cities
- Tucson, Arizona • Los Angeles, California • San Francisco, California + 18 more
- Conditions
- Melanoma (Skin)
- Interventions
- melphalan, sorafenib tosylate, gene expression analysis, protein expression analysis, western blotting, pharmacological study
- Drug · Genetic · Other
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2007
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Melanoma
- Interventions
- Dabrafenib, Trametinib, Metformin
- Drug
- Lead sponsor
- University of Louisville
- Other
- Eligibility
- 18 Years to 100 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 2
- States / cities
- Louisville, Kentucky
- Conditions
- Metastatic Melanoma
- Interventions
- Hypofractionated Radiation Therapy (HFRT), Nivolumab, Ipilimumab
- Radiation · Drug
- Lead sponsor
- Abramson Cancer Center at Penn Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2027
- U.S. locations
- 3
- States / cities
- Lancaster, Pennsylvania • Philadelphia, Pennsylvania • Salt Lake City, Utah
- Conditions
- Melanoma
- Interventions
- Nivolumab, HF10
- Drug
- Lead sponsor
- University of Utah
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Breast Cancer, Melanoma
- Interventions
- Lymphoseek
- Drug
- Lead sponsor
- Navidea Biopharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 163 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 8
- States / cities
- Birmingham, Alabama • La Jolla, California • San Francisco, California + 4 more
- Conditions
- Metastatic Melanoma, Cutaneous Melanoma
- Interventions
- HDI, KW2871
- Drug
- Lead sponsor
- Ludwig Institute for Cancer Research
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2014
- U.S. locations
- 2
- States / cities
- Chicago, Illinois • Pittsburgh, Pennsylvania
- Conditions
- Recurrent Melanoma, Stage IA Skin Melanoma, Stage IB Skin Melanoma, Stage IIA Skin Melanoma, Stage IIB Skin Melanoma, Stage IIC Skin Melanoma, Stage IIIA Skin Melanoma, Stage IIIB Skin Melanoma, Stage IIIC Skin Melanoma, Stage IV Skin Melanoma
- Interventions
- Diagnostic Microscopy, Fluorescein Sodium Injection, Laboratory Biomarker Analysis, Therapeutic Conventional Surgery
- Procedure · Drug · Other
- Lead sponsor
- Roswell Park Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2020
- U.S. locations
- 1
- States / cities
- Buffalo, New York
- Conditions
- Melanoma (Skin)
- Interventions
- comparative genomic hybridization, cytogenetic analysis, fluorescence in situ hybridization, immunohistochemistry staining method
- Genetic · Other
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 314 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2009
- U.S. locations
- 27
- States / cities
- Chicago, Illinois • Cedar Rapids, Iowa • Boston, Massachusetts + 17 more
- Conditions
- Melanoma, Skin Cancer
- Interventions
- Panobinostat, Ipilimumab
- Drug
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Malignant Neoplasm in the Brain, Metastatic Melanoma, Pathologic Stage IV Cutaneous Melanoma AJCC v8
- Interventions
- Ipilimumab, Pembrolizumab
- Biological
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Melanoma
- Interventions
- 4-peptide and 12-peptide melanoma vaccines
- Biological
- Lead sponsor
- Craig L Slingluff, Jr
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2000
- U.S. locations
- 1
- States / cities
- Charlottesville, Virginia
- Conditions
- Melanoma Stage III, Melanoma Stage IV, BRAF V600 Mutation
- Interventions
- Encorafenib Pill, Binimetinib Pill, Nivolumab
- Drug
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Tumor Skin, Metastatic Melanoma, Melanoma, Lung Cancer, Metastatic Lung Cancer, Non Small Cell Lung Cancer, Metastatic Non Small Cell Lung Cancer
- Interventions
- OBX-115
- Biological
- Lead sponsor
- Obsidian Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 254 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 13
- States / cities
- Tucson, Arizona • Los Angeles, California • Stanford, California + 8 more
- Conditions
- Melanoma (Skin)
- Interventions
- MART-1 antigen, aldesleukin, gp100 antigen, recombinant CD40-ligand, recombinant interferon gamma, recombinant interleukin-4, sargramostim, therapeutic autologous dendritic cells, therapeutic tumor infiltrating lymphocytes, tyrosinase peptide, Candida albicans skin test reagent
- Biological · Radiation
- Lead sponsor
- University of Southern California
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2006
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Cancer Risk, Cancer Predisposition Syndrome, Hereditary Cancer Prediction, Childhood Cancer Survivors, Adult Cancer Survivors, IARC Carcinogens, Smoking History, Lung Cancer, Ductal/Lobular Carcinoma, Barrett Esophagus, Pancreatic Precursor Lesions, Colonic Dysplasia/Adenomata, Non-Alcoholic Fatty Liver Disease, Non Alcoholic Steatohepatitis, Cirrhosis, High Grade Prostatic Epithelial Neoplasia, High-grade Bladder Urothelial Dysplasia/Carcinoma in Situ, Adenomatous Hyperplasia, High-risk Oral Precancerous Diseases, Melanocytic Lesion, Adult, Hematologic Malignancy, Lung; Node, Serous Tubal Intraepithelial Carcinoma, Endometrial Intraepithelial Neoplasia, Cervical and Endocervical Carcinoma in Situ, Vulvar Intraepithelial Neoplasia, Nephrogenic Rests, Benign Bone Lesions With Risk of Malignant Degeneration, Giant Cell Tumor, Osteochondroma, Spitz Nevus
- Interventions
- Samples
- Other
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- Not listed
- Enrollment
- 5,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2031
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Melanoma (Skin)
- Interventions
- O6-benzylguanine, carmustine
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2000
- U.S. locations
- 13
- States / cities
- Chicago, Illinois • Decatur, Illinois • Evanston, Illinois + 8 more
- Conditions
- Gastrointestinal Cancer, Liver Cancer, Pancreatic Cancer, Melanoma
- Interventions
- Not listed
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 133 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2017
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Locally Advanced Metastatic BRAF Mutant Melanoma
- Interventions
- LEE011, LGX818
- Drug
- Lead sponsor
- Array BioPharma
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 5
- States / cities
- Aurora, Colorado • Detroit, Michigan • New York, New York + 2 more
- Conditions
- Melanoma
- Interventions
- HDIL-2, recMAGE-A3 + AS15
- Drug · Biological
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2018
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Melanoma; Renal Cell Carcinoma
- Interventions
- Blood collection for laboratory studies, Data collection from medical record
- Other
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2027
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana